• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Acrivon Therapeutics Inc.

    4/25/25 8:32:08 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRV alert in real time by email
    DEFA14A
    0001781174falseDEFA14A00017811742024-01-012024-12-31

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE
    14A
    (Rule 14a-101)

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

     

     

    img244011982_0.jpg

     

    Acrivon Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)
     

    (Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

    img244011982_1.jpg

     

    Acrivon therapeutics p.o. Box 8016, cary, nc 27512-9903 your vote matters! Acrivon therapeutics, inc. Annual meeting of stockholders friday, june 13, 2025 11:00 am, eastern time annual meeting to be held virtually via the internet - please visit www.proxypush.com/acrv for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/acrv for a convenient way to view proxy materials, vote, and obtain directions to attend the meeting go to www.proxydocs.com/acrv to vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under united states securities and exchange commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before june 3, 2025. Meeting materials: notice of meeting and proxy statement & annual report on form 10-k important notice regarding the availability of proxy materials for the stockholders meeting to be held on june 13, 2025 for stockholders of record as of april 21, 2025 to order paper materials, use one of the following methods. To receive paper materials, you must make this request on or before june 3, 2025. Internet: www.investorelections.com/acrv call: 1-866-648-8133 email: [email protected] * if requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material. Your control number have the 12 digit control number located in the box above available when you access the website and follow the instructions. See reverse for full agenda copyright © 2025 betanxt, inc. Or its affiliates. All rights reserved


    img244011982_2.jpg

     

    Acrivon therapeutics acrivon therapeutics, inc.annual meeting of stockholders the board of directors recommends a vote: for all director nominees and for proposal 2 proposal 1. Election of class iii directors 1.01 peter blume-jensen, m.d., ph.d.1.02 derek dirocco, ph.d. 1.03 santhosh palani, ph.d., c.f.a..2. To ratify the appointment of pricewaterhousecoopers llp as the company's independent registered public accounting firm for the fiscal year ending december 31, 2025.3.the transaction of such other business as may properly come before the meeting.


    Get the next $ACRV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACRV

    DatePrice TargetRatingAnalyst
    5/5/2025$6.00Overweight
    Piper Sandler
    1/31/2025Overweight
    KeyBanc Capital Markets
    9/16/2024$16.00Neutral → Buy
    Ladenburg Thalmann
    4/29/2024Buy → Neutral
    Ladenburg Thalmann
    3/1/2024$14.00Mkt Outperform
    JMP Securities
    12/15/2023$17.00 → $12.00Buy
    Jefferies
    10/5/2023Buy
    Maxim Group
    6/2/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $ACRV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Acrivon Therapeutics Inc.

      SCHEDULE 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      5/15/25 5:24:39 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Acrivon Therapeutics Inc.

      S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)

      5/14/25 4:47:13 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Acrivon Therapeutics Inc.

      10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)

      5/14/25 4:16:08 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Acrivon Therapeutics with a new price target

      Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00

      5/5/25 8:30:14 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Acrivon Therapeutics

      KeyBanc Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Overweight

      1/31/25 8:29:16 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics upgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00

      9/16/24 7:17:32 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

      SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      7/10/24 8:34:52 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

      SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      7/10/24 8:29:53 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Acrivon Therapeutics Inc. (Amendment)

      SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      4/15/24 8:21:55 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Leadership Updates

    Live Leadership Updates

    See more
    • Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

      Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

      4/7/25 4:05:00 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

      WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year

      3/28/24 8:00:00 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

      WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi

      3/4/24 8:00:00 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

      Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mec

      5/14/25 4:10:00 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

      Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-2316 ahead of schedule with three dose-escalation cohorts completed; solid tumor shrinkage already observed at dose level three, well below the projected recommended Phase 2 dose WATERTOWN, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and dev

      4/25/25 8:00:00 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

      Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

      4/7/25 4:05:00 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perceptive Advisors Llc bought $20,000,500 worth of shares (2,353,000 units at $8.50) (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      4/15/24 8:53:49 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blume-Jensen Peter covered exercise/tax liability with 19,904 shares (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      5/23/25 4:58:19 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 4,320 units (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      5/16/25 4:21:13 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.50% to 36,323 units (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      5/16/25 4:20:06 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care